MEDICATIONS

Survodutide

A dual GLP-1/glucagon receptor agonist with potential benefits for both weight loss and liver health.

Survodutide is an investigational injection that mimics two natural hormones — GLP-1 and glucagon — to suppress appetite and boost calorie burning. Early clinical trials show significant weight loss, and it is also being studied for fatty liver disease.

Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist with balanced activity at both receptors. Phase 2 data demonstrated up to 18.7% body weight reduction at 46 weeks. Concurrent GCGR agonism promotes hepatic lipid oxidation and may provide additional benefit in metabolic dysfunction-associated steatotic liver disease (MASLD).

Survodutide's dual liver and weight benefits make it particularly relevant for patients with concurrent fatty liver disease. The NuLifeCare Singapore team monitors these developments to guide future treatment pathways.

⚕️

Medical Disclaimer

This library is for general education and does not replace individual assessment by a qualified healthcare professional. Always consult a doctor for medical advice, diagnosis, or treatment.

← Back to Weight Management Library